Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

Paul W. Young, Derek R. Buckle, Barrie C. C. Cantello, Helen Chapman, John C. Clapham, Paul J. Coyle, David Haigh, Richard M. Hindley, Julie C. Holder, Howard Kallender, Alison J. Latter, Kenneth W. M. Lawrie, Danuta Mossakowska, Gregory J. Murphy, Lynne Roxbee Cox and Stephen A. Smith
Journal of Pharmacology and Experimental Therapeutics February 1998, 284 (2) 751-759;
Paul W. Young
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek R. Buckle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barrie C. C. Cantello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Chapman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John C. Clapham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J. Coyle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Haigh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard M. Hindley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie C. Holder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard Kallender
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison J. Latter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth W. M. Lawrie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danuta Mossakowska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory J. Murphy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynne Roxbee Cox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen A. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A radioiodinated ligand, [125I]SB-236636 [(S)-(−)3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]3-[125I]iodophenyl]2-ethoxy propanoic acid], which is specific for the γ isoform of the peroxisomal proliferator activated receptor (PPARγ), was developed. [125I]SB-236636 binds with high affinity to full-length human recombinant PPARγ1 and to a GST (glutathioneS-transferase) fusion protein containing the ligand binding domain of human PPARγ1(KD = 70 nM). Using this ligand, we characterized binding sites in adipose-derived cells from rat, mouse and humans. In competition experiments, rosiglitazone (BRL-49653), a potent antihyperglycemic agent, binds with high affinity to sites in intact adipocytes (IC50 = 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively). Binding affinities (IC50) of other thiazolidinediones for the ligand binding domain of PPARγ1 were comparable with those determined in adipocytes and reflected the rank order of potencies of these agents as stimulants of glucose transport in 3T3-L1 adipocytes and antihyperglycemic agents in vivo: rosiglitazone > pioglitazone > troglitazone. Competition of [125I]SB-236636 binding was stereoselective in that the IC50 value of SB-219994, the (S)-enantiomer of an α-trifluoroethoxy propanoic acid insulin sensitizer, was 770-fold lower than that of SB-219993 [(R)-enantiomer] at recombinant human PPARγ1. The higher binding affinity of SB-219994 also was evident in intact adipocytes and reflected its 100-fold greater potency as an antidiabetic agent. The results strongly suggest that the high-affinity binding site for [125I]SB-236636 in intact adipocytes is PPARγ and that the pharmacology of insulin-sensitizer binding in rodent and human adipocytes is very similar and, moreover, predictive of antihyperglycemic activity in vivo.

Footnotes

  • Send reprint requests to: Dr. S. A. Smith, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW UK. E-mail: Stephen A Smith{at}sbphrd.com

  • Abbreviations:
    PPAR
    peroxisomal proliferator-activated receptor
    hPPAR
    human peroxisomal proliferator-activated receptor
    mPPAR
    murine peroxisomal proliferator-activated receptor
    GLUT-4
    glucose transporter isoform 4
    GST
    glutathione S-transferase
    AEBSF
    4-(2-aminoethyl)benzenesulfenylfluoride hydrochloride
    ETYA
    5,8,11,14-eicosatetraynoic acid
    HETE
    8-hydroxyeicosatetraenoic acid
    PCR
    polymerase chain reaction
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    DMSO
    dimethylsulfoxide
    BSA
    bovine serum albumin
    DPBS
    Dulbecco’s phosphate-buffered saline
    DMEM
    Dulbecco’s modified Eagle’s medium
    LBD
    ligand binding domain
    • Received June 17, 1997.
    • Accepted October 17, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 2
1 Feb 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

Paul W. Young, Derek R. Buckle, Barrie C. C. Cantello, Helen Chapman, John C. Clapham, Paul J. Coyle, David Haigh, Richard M. Hindley, Julie C. Holder, Howard Kallender, Alison J. Latter, Kenneth W. M. Lawrie, Danuta Mossakowska, Gregory J. Murphy, Lynne Roxbee Cox and Stephen A. Smith
Journal of Pharmacology and Experimental Therapeutics February 1, 1998, 284 (2) 751-759;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

Paul W. Young, Derek R. Buckle, Barrie C. C. Cantello, Helen Chapman, John C. Clapham, Paul J. Coyle, David Haigh, Richard M. Hindley, Julie C. Holder, Howard Kallender, Alison J. Latter, Kenneth W. M. Lawrie, Danuta Mossakowska, Gregory J. Murphy, Lynne Roxbee Cox and Stephen A. Smith
Journal of Pharmacology and Experimental Therapeutics February 1, 1998, 284 (2) 751-759;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Toxin and Subunit Specificity of Blocking Affinity of Three Peptide Toxins for Heteromultimeric, Voltage-Gated Potassium Channels Expressed in Xenopus Oocytes
  • Inhibition of Voltage-Dependent Sodium Channels by the Anticonvulsant γ-Aminobutyric Acid Type A Receptor Modulator, 3-Benzyl-3-Ethyl-2-Piperidinone
  • Antagonism of an Adenosine/ATP Receptor in FollicularXenopus Oocytes
Show more CELLULAR AND MOLECULAR PHARMACOLOGY

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics